Recently, we reported widespread intraneuronal prion protein (PrP) immunoreactivity in genetic Creutzfeldt-Jakob disease (CJD) associated with the E200K mutation. Here, we evaluated 6 cases of sporadic CJD MM type 1, 5 MV type 2, and 7 VV type 2 and compared their anatomical appearance with that of 29 E200K genetic CJD (gCJD) cases. We also performed double immunolabeling for ubiquitin, p62, early endosomal marker rab5, and immunogold electron microscopy in 3 cases. We identified 4 morphological types of intraneuronal PrP immunoreactivity: one type, defined as multiple globular structures, was significantly associated with a subset of E200K gCJD cases and was distinct from the intraneuronal small dotlike PrP immunoreactivity seen in sporadic CJD. Whereas the latter colocalized with rab5, there were single large (7.5 KmY15 Km) globular inclusion bodyYlike structures detected predominantly but not exclusively in E200K gCJD; these were immunoreactive in part for ubiquitin and p62 and showed focal F-tubulin immunoreactivity, suggesting aggresome features. Ultrastructural examination using immunogold revealed PrP localization in aggresome-like structures and in autophagic vacuoles. These findings suggest that the permanent production of mutant PrP in the E200K gCJD cases overwhelms the ubiquitin-proteasome system and shifts the balance toward selective macroautophagy and/or to ubiquitinated inclusion body and aggresome formation as a cytoprotective effort to sequester the mutant protein.
INTRODUCTION
Prion diseases are neurodegenerative disorders characterized by deposition of the disease-associated conformer of the cellular prion protein (PrP C ), termed PrP Sc , in the brain (1) . Neurodegenerative diseases are classified according to the predominant protein that accumulates as extracellular plaques, in synapses, or as intracellular inclusion bodies (2) . The proteinbased classification of conformational neurodegenerative diseases underpins the importance of cellular systems involved in protein homeostasis. The PrP is an aggregation-prone protein that is expected to stimulate the clearance mechanisms of affected cells. The main components of this housekeeping protein degradation network are the ubiquitin proteasome system (UPS) and the autophagy-lysosome pathway (3) . In addition, large intracellular protein inclusions called aggresomes have been described as key organelles in the segregation and clearance of toxic cytoplasmic misfolded proteins (4, 5) .
Although knowledge of the intracellular trafficking and the fate of PrP is incomplete, there are several observations that support involvement of these pathways (6, 7) . As in amyloid-A (AA) in Alzheimer disease, the processing of PrP and the conversion of PrP C into PrP Sc most likely involves the endosome-lysosome system (ELS) (8Y13). Intraneuronal PrP immunoreactivity (IR) has been described in idiopathic or sporadic Creutzfeldt-Jakob disease (sCJD), in particular, associated with type 2 proteinase-resistant PrP (14, 15) , as well as in different animal species and experimental models (16Y19). These must be distinguished from diffuse neuronal PrP immunostaining that is also detected in nondiseased individuals and that most likely represents the cellular form of PrP (20) . In contrast to tau, >-synuclein, TAR-DNA binding protein , and fused in sarcoma protein (FUS), PrP Sc has not yet been reported to form intracellular inclusions, defined as ubiquitinated aggregates in a consistent manner. Instead, it preferentially deposits in synapses or accumulates in the form of extracellular plaques (1) . It should be noted, however, that a study on ubiquitin immunostaining in CJD reported that cortical nerve cells contained scanty ubiquitinated dotlike inclusions (21) . Furthermore, inclusion bodyY like PrP immunopositivity was also reported in sCJD (22, 23) . The in-vitro findings in prion-infected or mutant PrP (PrP D177N )Y expressing cells that inhibition of proteasomes leads to aggresome formation raises the possibility that aggresomes may participate in the sequestration of PrP Sc (24Y26). Nevertheless, aggresomes have not yet been documented in human prion disease to date. Thus, this potentially cytoprotective mechanism seems to have less relevance for the pathogenesis of human disease.
One of the most frequent mutations associated with genetic prion disease of the CJD phenotype is the E200K mutation in the prion protein gene (PRNP). We recently reported a systematic study of E200K genetic CJD (gCJD) and demonstrated intracellular deposits of disease-associated PrP as a frequent event (27) ; we found them in approximately 33% of codon 129 MM homozygote cases and in 71% of MV heterozygotes. We also demonstrated that they regularly appear in subcortical regions and brainstem nuclei and may be prominent in deeper layers of the neocortex and CA1 subregion of the hippocampus (supplemental material in Kovacs et al [27] ). In the present study, we characterize these intracellular PrP deposits further and demonstrate that their distribution and morphology distinguish them from neuronrelated PrP IR seen in sCJD cases. Moreover, we find them not only in relation to the ELS, but partly forming aggresomelike structures.
MATERIALS AND METHODS

Case Selection
We examined 6 cases of sCJD MM type 1 (3 female, 3 male; mean duration of illness T SD, 3.3 T 0.5 months; mean age at death, 70 T 2.8 years), 5 MV sCJD type 2 (3 female, 2 male; 19.8 T 16.2 months; 67.6 T 4.2 years), and 7 sCJD VV type 2 (1 female, 6 male; 9.2 T 8.4 months; 69 T 4.8 years) to determine how many cases show neuron-related PrP. In these cases, we determined the morphological spectrum of neuronal-related PrP IR and compared the anatomical predominance with 29 E200K gCJD (15 MM, 13 MV, and 1 VV) cases (27 Evaluation of intraneuronal PrP IR was performed with a dichotomous approach (i.e. Byes/no[) in the following anatomical regions: frontal, cingulate, parietal, temporal, occipital cortex upper and deeper layers, caudate nucleus, putamen, globus pallidus, thalamus medial and lateral nuclei, hippocampus CA1 subregion and subiculum, raphe nuclei, pontine base nuclei, inferior olives, and dentate nucleus.
Double immunolabeling was performed using monoclonal anti-PrP (12F10), anti-ubiquitin, and polyclonal antirab5. The fluorescence-labeled secondary antibodies were Alexa Fluor (AF) 555 donkey antiYmouse IgG (1:200; Molecular Probes, Eugene, OR), AF 488 goat anti-rabbit (1:200; Molecular Probes), and Zenon AF 488 Mouse IgG 1 (Molecular Probes). The following combinations were applied: PrP/ ubiquitin (including Zenon AF) and PrP/Rab5. Double immunolabeling involving anti-PrP antibody was performed after pretreatment of the section with 20-minute heat-induced epitope retrieval with citrate buffer (pH 6), followed by 2-minute formic acid (96%). We evaluated double immunofluorescent labeling with a Zeiss LSM 510 confocal laser microscope.
Statistical Analysis
Chi-square statistics was performed to evaluate the proportion of cases showing different types of intraneuronal PrP IR and the proportion of involved anatomic regions showing intraneuronal PrP IR in those cases, which showed this type of IR. A value p G 0.05 was considered significant.
Paraffin-Embedded Tissue Blotting
This was performed with slight modifications according to published protocols (28) . Briefly, sections of formalinfixed, paraffin-embedded brain tissue (the same anatomical region as used for immunohistochemistry and electron microscopy) were placed onto a nitrocellulose membrane. Sections were treated with Proteinase K (Sigma-Aldrich) for 8 hours at 56-C. After washing, the membranes were treated with 3 mol/L guanidine isothiocyanate for 10 minutes. For immunodetection, we used antibody 3F4 (1:500; monoclonal mouse, Signet).
Immunoelectron Microscopy
After incubation of the deparaffinized tissue sections with anti-PrP (12F10) antibody, we applied Ultra Small gold-conjugated secondary antibody (Aurion, Wageningen, Netherlands) followed by silver enhancement. Slides were mounted with resin and examined by light microscopy. Selected areas containing immunoreactive cells were reembedded for ultrathin sectioning (29) . A JEOL-1011 electron microscope was used to analyze the ultrastructural localization of PrPspecific immunolabeling in the ultrathin sections.
RESULTS
Morphological Spectrum of Intraneuronal PrP IR
We distinguished 4 types of neuronal PrP immunopositivities as follows: type I, diffuse cytoplasmic PrP IR without distinct granular or dotlike appearance (we have evaluated this type in a previous comprehensive study [20] ); type II, many tiny dots ranging in size between 0.2 and 1.0 Km in the perikaryon, sometimes with a granular IR appearance; type III, distinct, small, globular, darkly immunostained cytoplasmic PrP-immunopositive profiles. These are always multiple, but their numbers are less than those of type II (usually 5Y10), and they are larger, with sizes ranging between 1.5 and 4.0 Km; type IV, distinct single larger globular structures with a size similar or larger than the nucleus of the neuron, with a range between 7.5 and 15 Km (Fig. 1A) . In addition, prominent diffuse synaptic PrP IR was associated with the socalled somatosynaptic pattern defined as tiny dots scattered in or above the microscopic focus level of the neuronal cytoplasm; this was not considered here and was seen in all subtypes of prion disease in this study.
Distribution of Intraneuronal PrP IR
There was no significant difference between the E200K gCJD cases and the pooled subtypes of sCJD with respect to the presence of any type of intraneuronal PrP IR. Type II neuronYrelated PrP IR was seen mainly in sCJD VV type 2 and also in MV type 2 cases, but not in MM type 1 and less in E200K cases (Figs. 1B, 2 ). When present, it appeared in several anatomical regions (Fig. 1C) ; the proportion of involved regions was significantly higher for E200K gCJD subtypes versus subtypes of sCJD, except for more regions in sCJD VV type 2 versus E200K MM gCJD.
Type III was significantly associated with a subset of E200K gCJD cases (MM, MV, VV) in an anatomical distribution (Figs. 1B, C; 2) that predominantly included the brainstem, thalamus, and deeper layers of the cortex (27) . Interestingly, where it was available in the examined section, this type was seen in cells of the periventricular germinal matrix (Fig. 2M) .
Type IV was predominantly seen in E200K cases in the inferior olive, basis pontis nuclei, thalamus, and less in the striatum; however, 3 sCJD VV type 2 (all in lateral thalamus and 1 in the dentate nucleus) and a single MM type 1 (dorsal raphe nucleus) also showed similar structures (Figs. 1C, 2) . In E200K gCJD cases, these were always seen in many neurons, whereas it was observed in single neurons in sCJD.
Light Microscopic Characterization of Intraneuronal PrP IR in E200K gCJD
Paraffin-embedded tissue blot for protease-resistant PrP proved that the intracellular immunopositivities are resistant to protease and thus represent disease-associated PrP (Fig. 3A) . Intracellular PrP deposits were not detected with an antibody raised against the N-terminal of PrP (Fig. 3B) . Moreover, some cells contained p62 (Fig. 3C) , but more cells showed ubiquitin-immunopositive structures (Fig. 3D, E) , which were immunonegative for >-synuclein, phospho-tau (AT8), phospho-TDP-43, and FUS (not shown). In addition, occasional neurons with type IV intraneuronal PrP IR exhibited perinuclear F-tubulin IR structures (Fig. 3F) . Double immunolabeling for ubiquitin and disease-associated PrP confirmed that these inclusion bodyYlike structures are partly ubiquitinated (Fig. 3G) ; the smaller dotlike PrP IR (types II and III) partly colocalized with the early endosomal marker rab5 (Fig. 3H ).
Ultrastructural Observations
We observed several large PrP-positive intracellular protein inclusions about the size of the nucleus in neurons of the inferior olive (Fig. 4A, B) . Immunogold particles representing disease-associated PrP accumulated within very large aggresome-like structures in the neighborhood of nuclei (Fig. 4A, B) . The PrP-positive granules were seen in close proximity to the rough endoplasmic reticulum (RER) (Fig. 4C) . The compact appearance of these particles strongly resembled preaggresomes (Fig. 4D) . Some neurons contained PrPpositive aggregates sequestered in spherical membrane-bound autolysosome-like organelles (Fig. 4E) . Several small vesicles and multivesicular bodies also showed PrP-specific immunolabeling (Fig. 4F, G) .
DISCUSSION
Here, we document the presence of neuronal intracytoplasmic inclusion bodies composed of the disease-associated PrP in gCJD associated with the E200K mutation in PRNP. We compared light microscopy with ultrastructural immunodetection of the disease-associated PrP in the same selected neurons in the human tissue samples (29) . Despite the limitations of postmortem paraffin-embedded tissue for electron microscopy, our observations are consistent with in vitro studies that address how the disease-associated (mutant) PrP is processed in the cytoplasm and whether it may form intracellular aggregates.
Punctuate intraneuronal PrP IR has been observed in animals and experimental models of prion disease as well as in sCJD, usually associated with certain molecular subtypes (7, 14Y19). In addition, inclusion bodyYlike structures were reported in 5 of 8 individuals with panencephalopathic type of CJD (without data on the codon 129) in the dentate nucleus (23) and in another report in the thalamus (22) . Although intraneuronal ubiquitin IR was also mentioned in a previous study (21) , we show here that indeed ubiquitinated inclusions may appear in E200K gCJD. Despite the presence of intraneuronal PrP IR in both sCJD and gCJD, the present study indicates that a certain morphological type (type III) is distinctive for a subset of the E200K gCJD cases. Interestingly, similar prominent intraneuronal PrP IR was recently described in a mouse model of the E200K mutation (30) . In addition, the type IV inclusion bodyYlike structures always involved more neurons in E200K gCJD than in sCJD cases. These were most numerous in dentate, inferior olivary nucleus, and basis pontis neurons. A comprehensive study of intraneuronal PrP in sheep brains, comparing the dorsal motor nucleus of the vagus and the olivary nuclei, previously also suggested that the variability in PrP processing by neurons could be cell dependent (19) .
Colocalization of the early endosomal marker Rab5 and mutant disease-associated PrP and the presence of PrP in multivesicular bodies support a role for the ELS in the pathogenesis of human genetic prion disease. Several studies have shown involvement of the ELS in experimental models of prion disease and in sCJD (8Y11, 31). Indeed, it was recently shown that a mildly acidic pH is needed for the destabilization of the human codon E200K mutant PrP, thereby underpinning the importance of endosomal processing and complementing our morphological observations (32, 33) .
In addition to the relation to the ELS, we detected diseaseassociated PrP in close proximity to RER cisterns and large (about the size of the neuronal nucleus) globular PrPimmunopositive structures. The relationship of mutant PrP to RER cisterns is well in line with the observation that untranslocated cytosolic PrP accumulates in the cytosol, is ubiquitinated, and serves as a substrate for proteasomal degradation (6) . Indeed, intracellular inclusion bodyYlike structures showed partial ubiquitin and p62 IR. Only extracellular but not intracellular PrP deposits were visualized using an antibody against the N-terminal fragment of PrP. On one hand, the frequently noted smaller intracytoplasmic IR most likely represents truncated PrP, in accordance to its colocalization with the early endosomal marker rab5. On the other hand, because of their partial ubiquitin and p62 IR, the occasional larger inclusion-like bodies most likely have a cytosolic origin; hence, their immunonegativity for N-terminal PrP could suggest conformational masking of the N-terminal epitope.
The appearance and the partial ubiquitin and p62 IR of the large PrP inclusion bodies suggest activation of autophagy and/or aggresome formation. The latter is also supported by the occasional presence of perinuclear neuronal F-tubulin IR. Recent observations support the notion that ubiquitin attached to misfolded protein substrates can be a common marker for either the UPS or the p62-mediated selective autophagy (34, 35) . Several data have documented the close relation and coordinated activity of the UPS and autophagy. When the cytosolic accumulation of misfolded proteins (i.e. mutant PrP) is permanent and the UPS (or the machinery required for substrate sorting to UPS) is consequently overwhelmed, autophagy may be induced as a compensatory cytoprotective mechanism (36, 37) . Significant neuronal autophagy has also been reported in scrapie-and CJD-infected mouse brains as well as in human CJD samples (38Y41). Moreover, induction of autophagy enhanced the lysosomal degradation of endosomally internalized PrP Sc in prion-infected cells (42, 43) . Nevertheless, further studies are needed to elucidate the exact role of the ubiquitin-and p62-dependent selective autophagy in the clearance of the cytosolic mutant PrP.
In addition to the previously mentioned protein housekeeping systems, aggresome formation has been recognized as a secondary defense mechanism. It sequesters and transforms potentially toxic misfolded aggregation-prone proteins into relatively inert inclusions for further degradation (4, 5, 44) . Thus, until now, aggresomes have been reported in prion models in vitro using proteasome and chaperone inhibitors but never in human prion diseases in situ. It has been shown that the retrotranslocated and untranslocated PrP accumulates and forms preaggresomes and mature aggresomes in neurons (24Y26, 45Y47).
It is generally accepted that gCJD with the E200K is not different from sCJD (mainly MM type-1 cases) (48) . However, there are several notable differences: (a) the presence of a distinct type of intraneuronal PrP IR in all codon 129 variants in a subset of cases; (b) the presence of a stripelike pattern of PrP IR in the cerebellar cortex that is associated with less prominent spongiform change in the molecular layer (27, 49) ; (c) a trend for more prominent involvement of the deeper layers irrespective of codon 129 constellation (a feature more characteristic of VV type 2 sCJD); (d) the lack of amyloid kuru-type plaques in cases with MV at codon 129 even when associated with type 2 proteinaseYresistant PrP (as characteristic for sCJD MV type 2); and (e) the frequent association with other neurodegeneration-related protein deposits (27) .
Our present findings argue for the following possibilities. First, the protein processing systems in gCJD are constantly overwhelmed, most likely for a longer period, whereas in (idiopathic) sCJD, a more dramatic course can happen with early neuronal death and bursting of the disease-associated PrP into the extracellular space. Second, postmortem examinations usually reflect a terminal stage, when neurons have already been damaged and some seemingly extracellular globular protein aggregates may represent formerly intracellular aggregates where the neuronal cell body was lysed, analogous to extracellular Lewy bodies in Parkinson disease. Indeed, we and others showed ubiquitination of larger extracellular PrP deposits in sCJD (21, 50) . This merits further studies in idiopathic CJD and may help clarify the role of aggresome formation in human prion diseases. From a diagnostic point of view, the presence of ubiquitin-or p62-IR intracellular inclusions that are negative for TDP-43, FUS, >-synuclein, or phospho-tau in a neurodegenerative disorder might raise the need for additional screening with anti-PrP immunohistochemistry.
In conclusion, our observations support the concept of a complex intracellular pathogenetic scenario involving diseaseassociated mutant PrP. According to our and other studies, the major players are the ELS, the UPS, autophagy and aggresome formation, which interact in a delicate balance. Involvement of this complex system might differ among different etiological forms of prion diseases. Because some aspects described here in gCJD differ from those observed in (idiopathic) sCJD forms, patients suffering from gCJD versus sCJD might require distinct therapeutic approaches.
